VGYAAN Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VGYAAN Pharmaceuticals, founded in 2018 and headquartered in New York, operates as a specialty pharmaceutical company with a core focus on generic drugs, OTC products, and biosimilars. Its business model integrates internal development with comprehensive contract development and manufacturing (CDMO) services for third parties. Following its acquisition by RK Pharma Inc., the company is positioned to enhance its capabilities in bringing clinically critical therapies to market, though specific pipeline details and financials are not publicly disclosed. The company emphasizes strategic partnerships and social responsibility as key components of its corporate strategy.

Generic Drugs

Technology Platform

Integrated contract development and manufacturing (CDMO) platform for generic and specialty drugs, including formulation development, analytical services, and cGMP manufacturing for solid oral dosages and biosimilars.

Opportunities

The growing global demand for cost-effective generic drugs and biosimilars presents a significant market opportunity.

Additionally, the expanding trend of outsourcing in pharma creates a strong tailwind for its CDMO business segment.

Risk Factors

Key risks include intense competition in generics and CDMO services, regulatory and compliance challenges in manufacturing, and execution risks associated with post-acquisition integration with RK Pharma Inc.

Competitive Landscape

VGYAAN competes in the crowded generic pharmaceutical and CDMO sector against large, established players like Teva, Mylan (Viatris), and Sun Pharma, as well as specialized CDMOs. Its differentiation relies on service reliability, cost-competitiveness, and its specialized focus on complex generics and biosimilars.

More companies in Small Molecule Drugs →More companies in United States →